An immunotherapy drug called Tecentriq (atezolizumab) extended the survival of lung cancer patients for several months longer than chemotherapy and caused fewer side effects, according to a new study.
The findings are from an early analysis of 850 patients with non-small cell lung cancer in a phase 3 trial funded by the drug’s makers.
According to the American Cancer Society, non-small cell lung cancer is the major form of the disease, comprising up to 85 percent of cases. Lung cancer remains the leading cancer killer in the United States, with more than 158,000 people expected to die from the disease this year.
The patients in the new trial had run out of treatment options. They received either Tecentriq or the chemotherapy drug docetaxel — the standard treatment for this type of cancer.
Click here to Read the full article: Immune-Focused Drug Shows Promise Against Lung Cancer
Share this entry
- Jaimie Krzynski, BSN/RN, is Appointed to the American Health Council’s Board of Nurses July 20, 2017
- American Health Council Names Diana Getsy-Holiday, RN, CD, CAP, ChT, BHT, ICADC to Nursing Board July 20, 2017
- The American Health Council Names Paul Aoun, DO/PhD, to Board of Physicians July 19, 2017
- The AHC Names Ferdinando Mirarchi, DO/FAAEM/FACEP, to its Board of Physicians July 18, 2017
- American Health Council Appoints Jonel Kinser, BSN/RN, to its Board of Nurses July 18, 2017
- American Health Council Names Husam Issa, MD, With Admission to Physician Board July 17, 2017